Viking Therapeutics CEO Brian Lian is watching the growth of interest in MASH and obesity but prepared to go it alone.

Roche has already signed several high-ticket deals this year, including the $3.5 billion acquisition of 89bio and Genentech’s $2.1 billion molecular glue pact with Orionis Biosciences.

In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how small ...

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with cystic fibrosis—an outcome William Blair found "potentially promising." ...

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.

Biopharma professionals have become increasingly likely to be dishonest when interviewing for jobs, based on BioSpace ...

Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.

As mRNA continues to enter and be adopted by the global healthcare community, the need to quickly validate and scale these ...

The deal focuses on ICT01, a monoclonal antibody being tested in acute myeloid leukemia. ImCheck is also developing assets in ...

While the threat of tariffs dies down for the pharma industry, President Donald Trump is reportedly weighing a new ...

Seven in 10 U.S. hiring managers say their company usually considers employing overqualified applicants, according to a ...

Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN ...